National Pharmaceutical Pricing Authority

(Published in Part II, Section 3, Sub-section (ii) of

the Gazette of India, Extraordinary, dated the 1^st October, 2008)

Government of India

Ministry of Chemicals and Fertilizers

National Pharmaceutical Pricing Authority

New Delhi, the 1^st October, 2008

ORDER

S.O. 2350(E)- In exercise of the powers, conferred by sub-paragraph (1)/(2)/(4) of paragraph 8 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes/revises the prices as specified in column (5) of the table hereto annexed as the retail price/revised retail price, exclusive of excise duty, Sales Taxes/VAT and local taxes, if any, and in column (6) as equivalent MRP inclusive of excise duty, education cess, Sales Tax/VAT in relation to each of the formulation specified in the corresponding entry in column (2) of the said table with the pack size specified in the corresponding entries in column (3) thereof; manufactured/imported by M/s. Eli Lilly and Company (I) Pvt. Ltd.

TABLE

Sl. No.	Name of the formulation	Pack Size	Existing Retail Price Excise (Rs.)	Retail Price without Excise Duty Sales Tax /VAT and Local Tax, if any (Rs.)	Equivalent MRP* inclusive of all taxes (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1	Monocomponent Insulin Huminsulin 30/70 – 40 IU/ml Vias (30% Neutral Insulin Solution & 70% Isophane Suspension Human) Each ml of 30% Neutral Insulin Solution &70% Isophane Suspension Human contains: 40 IU Humaninsulin Ph. Eur. (r-DNA origin) as active ingredient Batch No. A483471 / Qty. 47978 Vials imported Batch No. A482795 / Qty. 47726 Vials imported Batch No. A490279 / Qty. 46018 Vials imported Batch No. A496426 / Qty. 1806 Vials imported Batch No. A490280 / Qty. 47176 Vials imported Batch No. A490283 / Qty. 47327 Vials imported Batch No. A490281 / Qty. 47516 Vials imported Batch No. A490277 / Qty. 47894 Vials imported Batch No. A496428 / Qty. 46908 Vials imported Batch No. A496425 / Qty. 47599 Vials imported Batch No. A496427 / Qty. 47329Vials imported	10ml vials	163.65	158.00	164.32
2	Monocomponent Insulin Humalog Pen 100 IU/m (Insulin Lispro) Each ml of Insulin Lispro contains100 IU Insulin Lispro Ph. Eur.(r-DNA origin) as active ingredient Batch No. A473669H / Qty. 12000 Disposable Pens imported No. A488168F/ Qty. 10100 Disposable pen imported	3ml Disposable Pen	523.23	522.73	543.64
3	Monocomponent Insulin Humalog Mix 50 Pen 100IU/ml Disposable Pen50% Insulin Lispro and 50% Insulin Lispro Protamine Suspension, r-DNA Origin Anti Diabetic (Insulin Lispro) Each ml of 50% Insulin Lispro and 50% Insulin Lispro Protamine suspension contains 100 IU Insulin Lispro Ph. Eur. (r-DNA origin) as active ingredient Batch No. A451125N / Qty. 7970 Disposable Pens imported No. A502647A/ Qty. 20000 disposable pen imported	3ml Disposable Pen	523.23	523.23	543.64
4	Monocomponent Insulin Humalog Mix 25 Pen 100IU/ml 25% Insulin Lispro and 75% Insulin Lispro Protamine suspension, r-DNA origin, Anti Diabetic Each ml of 25% Insulin Lispro and75% Insulin Lispro Protamine suspension contains 100 IU Insulin Lispro Ph. Eur. (r-DNA origin) as active ingredient Batch No. A456933D / Qty. 10000 Disposable Pens imported	3ml Disposable Pen	524.94	523.53	544.47
5	Monocomponent Insulin Humalog Mix 25 100 IU/ml 25% Insulin Lispro and 75% InsulinLispro Protamine suspension, r-DNA origin, Anti Diabetic Each ml of 25% Insulin Lispro and 75% Insulin Lispro Protamine suspension contains100 IU Insulin Lispro (r-DNA origin) as active ingredient Batch No. A473665D / Qty. 17630 Cartridges imported No. A463792C/ Qty. 20125 Cartridge Imported No. A463792E/ Qty. 25215Cartridge Imported	3ml Cartridge	397.00	397.26	413.15
6	Monocomponent Insulin Humalog 100 IU/ml (Insulin Lispro) Anti Diabetic Each ml of Insulin Lispro contains100 IU (3.5mg) Insulin Lispro (r-DNA origin) as active ingredient Batch No. A493303D / Qty. 10000 Cartridges imported No. A469853E/ Qty. 15600 Cartridge Imported No. A488168C, Qty. 22095 Cartridge Imported	3ml Cartridge	397.00	397.26	413.15
7	Monocomponent Insulin Humalog Mix 50 Pen 100IU/ml 50% Insulin Lispro and 50% Insulin Lispro Protamine Suspension, r-DNA Origin Anti Diabetic (Insulin Lispro) Each ml of 50% Insulin Lispro and50% Insulin Lispro Protamine suspension contains 100 IU Insulin Lispro (r-DNA Origin) as Active ingredient No. A495830C/ Qty. 34250 Cartridge Imported	3ml Cartridge	397.00	397.26	413.15
8	Monocomponent Insulin Huminsulin Regular 100 IU/ml (Insulin Human Injection) Anti DiabeticEach ml of Insulin Human Injection contains : 100IU Human Insulin Ph.Eur. (r-DNA Origin)as active ingredient No. A490067E, Qty. 40000 Cartridge Imported	3ml Cartridge	203.02	203.05	211.17
9	Monocomponent Insulin Huminsulin 30/70 – 100 IU/ml (30% Neutral Insulin Solution & 70% Isophane Suspension Human) Anti Diabetc Each ml of 30% Neutral Insulin Solution &70% Isophane Suspension Human contains: 100 IU Human insulin Ph. Eur. (r-DNA origin) as active ingredient Batch No. A483461E / Qty. 299965 Cartridges imported	3ml Cartridge	203.02	203.02	211.17

*Subject to actual payment of Government levies/taxes, as applicable.

Note :

(a) The prices fixed are the maximum retail prices in column no. (6) (inclusive of excise duty, sales tax/VAT and local taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any ground therefrom, unless specifically permitted by the Government/NPPA through an order.

(b) The companies / manufacturers may added taxes only if they have paid actually to the Government on the price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.

(c) For different packing material used or any special feature claimed, companies are required to approach NPPA for approval/fixation of specific prices.

(d) The manufacturer and marketing company for the above said formulation shall be required to take the requisite prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.

(e) These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub para 14(1) of DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of the Drugs (Prices Control) Order, 1995.

(f) These prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.

PN/104/2008/F

F. No. 8(13)/2008/D.P./NPPA-Div.-II

(RAJIV WADHAWAN)

Deputy Director

Last Page Updated: 01-06-2019

Note :Website Content Managed by National Pharmaceutical Pricing Authority Ministry of Chemicals and Fertilizers, Designed, Developed and Hosted by National Informatics Centre Services Inc.(NICSI)